Partners | Office of Cancer Clinical Proteomics Research

Partners

Developmental Studies Hybridoma Bank at the University of Iowa

NCI’s OCCPR works closely with The University of Iowa's Developmental Studies Hybridoma Bank (DSHB) that distributes all hybridomas and monoclonal antibodies from NCI's Clinical Proteomic Technologies for Cancer initiative (CPTC). DSHB supplies researchers with monoclonal antibodies, which may be ordered as tissue culture supernatants, ascites, or concentrate; selected hybridomas are also available as frozen or growing cells.

DNASU Plasmid Repository of the Biodesign Institute at Arizona State University

NCI’s OCCPR works with The DNASU Plasmid Repository of the Biodesign Institute at Arizona State University (DNASU), a central repository for plasmid clone collections and distribution. DNASU serves as a repository for CPTC plasmid clone collections and distribution.

Human Protein Atlas

NCI’s OCCPR closely collaborates with the Human Protein Atlas (HPA) that uses tissue microarrays to further characterize monoclonal antibodies produced from CPTC after their characterization by the ACL at NCI-Frederick. HPA’s characterization data are publicly available, and presented as high-resolution images of immunohistochemically stained tissues and cell lines annotated with links to proteins for specific genes or by browsing individual chromosomes.

Millipore

NCI’s OCCPR collaborates with Millipore to distribute a subset of the CPTC antibodies to the research community. These antibodies are designated with CPTC prefix with characterization data available from both Millipore and CPTC.

The Virginia G. Piper Center for Personalized Diagnostics of the Biodesign Institute at Arizona State University

NCI’s OCCPR works closely with The Center for Personalized Diagnostics of the Biodesign Institute at Arizona State University to apply NAPPA technology in the characterization of monoclonal antibodies from CPTC (with data publicly available).

Affinomics

NCI’s OCCPR collaborates with Europe’s Affinomics Consortium via a memorandum of understanding (MOU) to facilitate coordination and avoid duplication in the production of cancer-associated proteins and affinity reagents, and the subsequent characterization with public dissemination of products and data to the research community.